Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Hancock Jaffe Laboratories Inc is a medical devices business based in the US. Hancock Jaffe Laboratories shares (HJLI) are listed on the NASDAQ and all prices are listed in US Dollars. Hancock Jaffe Laboratories employs 19 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$9.88|
|52-week range||$4.99 - $11.82|
|50-day moving average||$9.02|
|200-day moving average||$6.95|
|Wall St. target price||$26.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||1.33%|
|1 month (2021-09-24)||-0.70%|
|3 months (2021-07-26)||57.58%|
|6 months (2021-04-26)||51.77%|
|1 year (2020-10-26)||2,815.31%|
|2 years (2019-10-25)||1,166.67%|
|3 years (2018-10-26)||375.00%|
|5 years (2016-10-22)||N/A|
|Gross profit TTM||$-4,252,249|
|Return on assets TTM||-30.58%|
|Return on equity TTM||-55.76%|
|Market capitalisation||$98.3 million|
TTM: trailing 12 months
There are currently 710,903 Hancock Jaffe Laboratories shares held short by investors – that's known as Hancock Jaffe Laboratories's "short interest". This figure is 48.3% up from 479,514 last month.
There are a few different ways that this level of interest in shorting Hancock Jaffe Laboratories shares can be evaluated.
Hancock Jaffe Laboratories's "short interest ratio" (SIR) is the quantity of Hancock Jaffe Laboratories shares currently shorted divided by the average quantity of Hancock Jaffe Laboratories shares traded daily (recently around 279883.07086614). Hancock Jaffe Laboratories's SIR currently stands at 2.54. In other words for every 100,000 Hancock Jaffe Laboratories shares traded daily on the market, roughly 2540 shares are currently held short.
However Hancock Jaffe Laboratories's short interest can also be evaluated against the total number of Hancock Jaffe Laboratories shares, or, against the total number of tradable Hancock Jaffe Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hancock Jaffe Laboratories's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Hancock Jaffe Laboratories shares in existence, roughly 80 shares are currently held short) or 0.0837% of the tradable shares (for every 100,000 tradable Hancock Jaffe Laboratories shares, roughly 84 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Hancock Jaffe Laboratories.
Find out more about how you can short Hancock Jaffe Laboratories stock.
We're not expecting Hancock Jaffe Laboratories to pay a dividend over the next 12 months.
Hancock Jaffe Laboratories's shares were split on a 1:25 basis on 29 November 2020. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Hancock Jaffe Laboratories shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Hancock Jaffe Laboratories shares which in turn could have impacted Hancock Jaffe Laboratories's share price.
Over the last 12 months, Hancock Jaffe Laboratories's shares have ranged in value from as little as $4.99 up to $11.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hancock Jaffe Laboratories's is 1.5404. This would suggest that Hancock Jaffe Laboratories's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Hancock Jaffe Laboratories, Inc. , a medical device company, develops and sells tissue-based solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. It engages in the development and manufacture of bioprosthetic medical devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat reflux associated with chronic venous insufficiency; and the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries. The company was founded in 1987 and is headquartered in Irvine, California. Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.